Sanofi Plavix Patent: Generic Firms Raise "Substantial Challenge" To Validity, Aventis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Analyses of the clopidogrel patent litigation suggest Dr. Reddy's and Apotex raise "serious questions" on anticipation, obviousness and "double patenting," Aventis says. Reviews are part of Aventis' ongoing defense against Sanofi's hostile takeover bid.
You may also be interested in...
Aventis Offers Plan To Protect Shareholders From Sanofi Plavix Patent Risk
The Aventis board also votes to enter into negotiations with Novartis, thereby satisfying one of Novartis’ two prerequisites for commencing merger talks. Aventis will “pursue discussions” with French and German authorities to address their concerns about an Aventis/Novartis deal.
Aventis Offers Plan To Protect Shareholders From Sanofi Plavix Patent Risk
The Aventis board also votes to enter into negotiations with Novartis, thereby satisfying one of Novartis’ two prerequisites for commencing merger talks. Aventis will “pursue discussions” with French and German authorities to address their concerns about an Aventis/Novartis deal.
Aventis Ad Campaign Challenges Sanofi Merger Bid
Aventis has launched an advertising campaign in European newspapers and magazines arguing against Sanofi-Synthelabo's $60 bil. hostile takeover bid